Treatment of Hypertension in Metabolic Syndrome Subjects with Amlodipine and Olmesartan—Effects on Oxidized Non-Esterified Free Fatty Acids and Cytokine Production

[1] Dalla Libera L(2001)Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure Circulation 103 2195-200

[2] Ravara B(1998)Tumour necrosis factor alpha activates a p22phox-based nadh oxidase in vascular smooth muscle Biochem J 329 653-7

[3] Angelini A(2005)Diagnosis and management of the metabolic syndrome: An American Heart Association/national heart, lung, and blood institute scientific statement Circulation 112 2735-52

[4] Rossini K(2004)C18 hydroxy fatty acids as markers of lipid peroxidation ex vivo and in vivo Scand J Clin Lab Invest 64 457-68

[5] Sandri M(2005)Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects J Lab Clin Med 145 83-7

[6] Thiene G(1999)The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein e deficient mice Cardiovasc Res 44 579-87

[7] De Keulenaer GW(1998)Ace inhibitor quinapril reduces the arterial expression of nf-{kappa}b-dependent proinflammatory factors but not of collagen i in a rabbit model of atherosclerosis Am J Pathol 153 1825-37

[8] Alexander RW(1999)Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in cynomolgus monkeys fed a high-cholesterol diet Br J Pharmacol 128 523-9

[9] Ushio-Fukai M(1999)Comparison of the effects of at1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis[ast] Am J Hypertens 12 28-34

[10] Ishizaka N(2000)Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia Circulation 101 1586-93

[1] Dalla Libera L(2001)Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure Circulation 103 2195-200

[2] Ravara B(1998)Tumour necrosis factor alpha activates a p22phox-based nadh oxidase in vascular smooth muscle Biochem J 329 653-7

[3] Angelini A(2005)Diagnosis and management of the metabolic syndrome: An American Heart Association/national heart, lung, and blood institute scientific statement Circulation 112 2735-52

[4] Rossini K(2004)C18 hydroxy fatty acids as markers of lipid peroxidation ex vivo and in vivo Scand J Clin Lab Invest 64 457-68

[5] Sandri M(2005)Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects J Lab Clin Med 145 83-7

[6] Thiene G(1999)The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein e deficient mice Cardiovasc Res 44 579-87

[7] De Keulenaer GW(1998)Ace inhibitor quinapril reduces the arterial expression of nf-{kappa}b-dependent proinflammatory factors but not of collagen i in a rabbit model of atherosclerosis Am J Pathol 153 1825-37

[8] Alexander RW(1999)Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in cynomolgus monkeys fed a high-cholesterol diet Br J Pharmacol 128 523-9

[9] Ushio-Fukai M(1999)Comparison of the effects of at1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis[ast] Am J Hypertens 12 28-34

[10] Ishizaka N(2000)Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia Circulation 101 1586-93